Chemoselective Acylation of Nucleosides.

Yu Tang, Rebecca L Grange, Oliver D Engl, Scott J Miller

Abstract read

In one paragraph

Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Chemoselective Acylation of Nucleosides.Chemistry (Weinheim an der Bergstrasse, Germany) · 2022
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yu TangDepartment of Chemistry, Yale University, New Haven, CT 06520, USA.ORCID http://orcid.org/0000-0002-9537-0420

Rebecca L GrangeProcess Chemistry & Development, Takeda Pharmaceuticals International Co., Cambridge, MA 02139, USA.

Oliver D EnglProcess Chemistry & Development, Takeda Pharmaceuticals International Co., Cambridge, MA 02139, USA.

Scott J MillerDepartment of Chemistry, Yale University, New Haven, CT 06520, USA.ORCID http://orcid.org/0000-0001-7817-1318

Funding

Site-Selective Catalysis for Bioactive Scaffold DiversificationR35GM132092 · NIGMS · YALE UNIVERSITY · PI Scott J Miller · 2019 to 2026

$6.3M

NIGMS NIH HHS R35 GM132092NIH HHS NIGMS R35-132092Takeda Pharmaceuticals International

6 · The paper itself

Abstract

Acylated nucleoside analogues play an important role in medicinal chemistry and are extremely useful precursors to various other nucleoside analogues. However, chemoselective acylation of nucleosides usually requires several protection and deprotection steps due to the competing nucleophilicity of hydroxy and amino groups. In contrast, direct protecting-group-free chemoselective acylation of nucleosides is a preferred strategy due to lower cost and fewer overall synthetic steps. Herein, a simple and efficient chemoselective acylation of nucleosides and nucleotides under mild reaction conditions, giving either O- or N-acylated products respectively with excellent chemoselectivity is reported.

Indexed as

NucleosidesNucleotidesAcylationChemistry, PharmaceuticalNucleosidesNucleotidesacylationchemoselectivitynucleosidessynthetic methods

Identifiers

PMID35730928

DOI10.1002/chem.202201661

PMCPMC9481663

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.